Company / Operating Income
Astria Therapeutics, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$111.6M
FY2024
5-year range
-$195.0M / -$37.4M
FY2020-FY2024
Trend
-34.4%
vs FY2023
Sector context
#100 of 204
Health Care
What the data says
At -$112M, Astria Therapeutics, Inc.'s operating income ranks #100 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$195M in FY2021 to -$26M in FY2018.
Based on SEC 10-K filings.
-$112M in FY2024.
Declined from -$54M to -$112M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#100 of 204 in Health CareTop 49% of 204This company -$111.6M Sector average $107.7M
▼
-203.6% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 34.4% year-over-year.
- Ranks #100 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$111.6M | -34.4% |
| FY2023 | -$83.0M | -55.2% |
| FY2022 | -$53.5M | +72.6% |
| FY2021 | -$195.0M | -420.8% |
| FY2020 | -$37.4M | -38.2% |
| FY2019 | -$27.1M | -2.7% |
| FY2018 | -$26.4M | +2.7% |
| FY2017 | -$27.1M | +23.8% |
| FY2016 | -$35.6M | -12.3% |
| FY2015 | -$31.7M | -46.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026